What question did this study set out to answer?

This study aims to understand the structural mechanisms by which SLFN5 regulates Type I interferon signaling and glioblastoma proliferation.

May 29, 2026Open Access

SLFN5 restrains type I interferon responses and promotes glioblastoma via its N-terminal Schlafen core domain

Puntos clave

This study aims to understand the structural mechanisms by which SLFN5 regulates Type I interferon signaling and glioblastoma proliferation.
Functional dissection of SLFN5 domains to assess their roles in IFN-stimulated gene expression and tumorigenesis.
Partial deletions and substitutions in the core domain to evaluate effects on chromatin association and SLFN5 activity.
Structural comparison between human and murine SLFN5 to establish functional conservation.
Deletions in the N-terminal core domain disrupt chromatin association, leading to de-repression of immune checkpoint genes like PD-L1 and PD-L2.
The C-terminal ATPase/helicase activity does not affect transcriptional repression, highlighting its limited role in tumor promotion.
Murine SLFN5 is shown to be a functional ortholog of human SLFN5, indicating the conservation of its biological functions.

Resumen

Abstract Schlafen 5 (SLFN5) is an important regulator of Type I interferon (IFN-I) signaling and tumorigenesis, yet the structural basis for its biologic activity remains unclear. Here, we dissect functional domains of SLFN5 and uncover a key role for its N-terminal Schlafen core domain in IFN-stimulated gene (ISG) expression and glioblastoma proliferation, independently of the SWAVDL motif and the C-terminal Walker A/B motifs. Partial deletions within the core domain or substitution of two arginine residues (R271E/R326E) near the zinc finger motif disrupt chromatin association and phenocopy SLFN5 loss, including de-repression of ISGs that act as immune checkpoints, such as PD-L1 and PD-L2. In contrast, the C-terminal ATPase/helicase activity is dispensable for transcriptional repression and tumor-promoting functions. Structural comparison of human and mouse SLFN5 revealed a conserved architecture, and experimental evidence demonstrates that murine SLFN5 is a functional ortholog of human SLFN5. These findings establish SLFN5 as a key transcriptional modulator of malignant glioblastoma growth by dampening IFN-I responses and have implications for the development of future immunotherapy approaches.

Me gusta

Guardar

Ver artículo completo